A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512108-20-00

Enrollment

Registered

2024-07-01

Start date

2022-03-16

Completion date

Unknown

Last updated

2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder

Brief summary

Safety and tolerability are assessed using the frequency of unique subjects with: SAE; AEs leading to discontinuation; AEs judged to be related to study medication; and clinically significant laboratory abnormalities that are observed over the course of treatment.

Interventions

DRUGTroriluzole

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety and tolerability are assessed using the frequency of unique subjects with: SAE; AEs leading to discontinuation; AEs judged to be related to study medication; and clinically significant laboratory abnormalities that are observed over the course of treatment.	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026